GlassScriptPhysician profile
Michael S Miller
NPI 1730122268
$53,192.26
in general payments reported to CMS, 2019-2025
62 companies · $4,960 in 2025
The $4,960 reported for 2025 was more than what 90% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,760 · 2020: $1,718 · 2021: $26K · 2022: $10K · 2023: $4,197 · 2024: $3,692 · 2025: $4,960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,608.83 |
| Education | $240.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $31,956.55 | 2021-2024 | Lucemyra, Zimhi |
| Mdd US Operations, LLC | $2,961.34 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $2,305.29 | 2022-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,175.56 | 2020-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $1,666.51 | 2020-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $1,632.58 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Janssen Pharmaceuticals, INC | $1,510.10 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Abbvie INC. | $936.02 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $828.42 | 2022-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $542.22 | 2024-2025 | Cobenfy |
| Indivior INC. | $536.25 | 2019-2025 | Sublocade, Perseris |
| Merz North America, INC. | $466.21 | 2022-2023 | Xeomin |
| Neurocrine Biosciences, INC. | $464.66 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $428.66 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $414.86 | 2021-2022 |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $362.15 | 2021-2025 | Aristada, Lybalvi |
| Biodelivery Sciences International, INC. | $317.37 | 2019-2021 | |
| Axsome Therapeutics, INC. | $308.98 | 2022-2025 | Auvelity |
| Sumitomo Pharma America, INC. | $282.35 | 2023-2024 | Aptiom |
| Arbor Pharmaceuticals, INC. | $279.66 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $264.33 | 2019-2022 | |
| Almatica Pharma LLC | $240.59 | 2021-2023 | Loreev Xr, Gralise |
| Jazz Pharmaceuticals INC. | $230.25 | 2025 | |
| Scilex Pharmaceuticals INC. | $196.27 | 2019-2021 | |
| Harmony Biosciences LLC | $158.59 | 2020-2025 | Wakix |
| Tactile Systems Technology INC | $137.41 | 2019-2020 | |
| Corium, LLC | $134.10 | 2023-2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $133.88 | 2022-2024 | Quviviq |
| Gilead Sciences, INC. | $115.75 | 2023-2024 | |
| Luye Pharma (USA) LTD. | $102.86 | 2025 | Erzofri Extended-Release |
| Koya Medical, INC. | $96.12 | 2021 | |
| Triad Life Sciences INC. | $86.73 | 2021-2022 | |
| Novo Nordisk INC | $82.93 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Convatec INC. | $72.74 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $71.27 | 2022-2025 | Belbuca |
| Kerecis Limited | $68.28 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Noven Therapeutics, LLC | $65.44 | 2023-2025 | Secuado, Xelstrym |
| Orexo US, INC. | $52.10 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $47.54 | 2023 | Horizant |
| Astrazeneca Pharmaceuticals LP | $40.07 | 2020 | |
| Lilly USA, LLC | $38.99 | 2024-2025 | Mounjaro, Zepbound |
| Kci USA, INC. | $32.61 | 2019 | |
| Madrigal Pharmaceuticals | $28.48 | 2025 | Rezdiffra |
| Nevro Corp. | $28.01 | 2020-2023 | Senza |
| Hartmann USA, INC. | $25.59 | 2025 | Zetuvit Plus 10x10 P10 |
| Vertex Pharmaceuticals Incorporated | $24.29 | 2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.65 | 2022 | |
| Reprise Biomedical, INC. | $18.47 | 2025 | Miro 3d |
| Averitas Pharma INC. | $18.36 | 2025 | Qutenza |
| Integra Lifesciences Corporation | $17.39 | 2022 | |
| Endo Pharmaceuticals INC. | $16.90 | 2022 | |
| Ironshore Pharmaceuticals INC. | $15.33 | 2022 | |
| Braeburn INC. | $15.11 | 2023 | Brixadi |
| Stryker Corporation | $14.86 | 2023 | Stryker |
| Merck Sharp & Dohme LLC | $14.17 | 2021 | |
| Neuronetics, INC. | $14.10 | 2023 | Neurostar Tms Therapy System |
| Allergan, INC. | $13.60 | 2021 | |
| Kaleo, INC. | $13.41 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.34 | 2021 | |
| Hollister Incorporated | $13.21 | 2021 | |
| Pfizer INC. | $12.44 | 2019 | |
| Molnlycke Health Care US, LLC | $10.96 | 2023 | Mesalt, Mepilex Border Sacrum, Mepilex Xt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.